tranexamic acid has been researched along with Kidney Failure in 13 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
Kidney Failure: A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.
Excerpt | Relevance | Reference |
---|---|---|
" The aims of this study were to characterize the inter-patient variability associated with pharmacokinetic parameters and to recommend a new dosing adjustment based on the BART dosing regimen for CPB patients with chronic renal dysfunction (CRD)." | 1.42 | Pharmacokinetic modeling of tranexamic acid for patients undergoing cardiac surgery with normal renal function and model simulations for patients with renal impairment. ( Bies, RR; Jerath, A; Pang, KS; Wąsowicz, M; Yang, QJ, 2015) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 6 (46.15) | 29.6817 |
2010's | 6 (46.15) | 24.3611 |
2020's | 1 (7.69) | 2.80 |
Authors | Studies |
---|---|
Hulde, N | 2 |
Zittermann, A | 2 |
Deutsch, MA | 2 |
von Dossow, V | 2 |
Gummert, JF | 2 |
Koster, A | 2 |
Makhija, N | 1 |
Sarupria, A | 1 |
Kumar Choudhary, S | 1 |
Das, S | 1 |
Lakshmy, R | 1 |
Kiran, U | 1 |
Fisher, C | 1 |
Mo, A | 1 |
Warrillow, S | 1 |
Smith, C | 1 |
Jones, D | 1 |
Yang, QJ | 1 |
Jerath, A | 1 |
Bies, RR | 1 |
Wąsowicz, M | 1 |
Pang, KS | 1 |
Martin, K | 1 |
Wiesner, G | 1 |
Breuer, T | 1 |
Lange, R | 1 |
Tassani, P | 1 |
Barnum, JL | 1 |
Sistino, JJ | 1 |
Pasquali, SK | 1 |
Li, JS | 1 |
He, X | 1 |
Jacobs, ML | 1 |
O'Brien, SM | 1 |
Hall, M | 1 |
Jaquiss, RD | 1 |
Welke, KF | 1 |
Peterson, ED | 1 |
Shah, SS | 1 |
Jacobs, JP | 1 |
Hutton, B | 1 |
Joseph, L | 1 |
Fergusson, D | 1 |
Mazer, CD | 2 |
Shapiro, S | 1 |
Tinmouth, A | 1 |
Mangano, DT | 1 |
Tudor, IC | 1 |
Dietzel, C | 1 |
Bremerich, DH | 1 |
Strametz, R | 1 |
Kirchner, R | 1 |
Moritz, A | 1 |
Zwissler, B | 1 |
Body, SC | 1 |
Mouton, R | 1 |
Finch, D | 1 |
Davies, I | 1 |
Binks, A | 1 |
Zacharowski, K | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean Delivery: A Randomized Controlled Trial[NCT03364491] | Phase 3 | 11,000 participants (Actual) | Interventional | 2018-03-15 | Completed | ||
DEPOSITION: Pilot Study Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery[NCT03376061] | Phase 4 | 97 participants (Actual) | Interventional | 2017-12-21 | Completed | ||
The Effect of Tranexamic Acid (TXA) on Blood Loss and Transfusion Rates in Burn Wound Surgery - A Randomized, Double-Blinded Placebo-Controlled Trial[NCT02753816] | 25 participants (Actual) | Interventional | 2016-04-30 | Terminated (stopped due to Study enrollment and goals unable to be reached.) | |||
Influence of Elevated Baseline Serum Creatinine and Body Composition on Acute Kidney Injury in Cardiac Surgery - The InCreAS Trial[NCT02598271] | 200 participants (Actual) | Observational | 2016-10-31 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
[Key secondary outcome] Change in hemoglobin from the most recent measured before delivery to lowest measured in the 48 hours after delivery (NCT03364491)
Timeframe: from 4 weeks before delivery to 48 hours postpartum
Intervention | grams per deciliter (Mean) |
---|---|
Tranexamic Acid | -1.8 |
Placebo | -1.9 |
Mother's length of stay from delivery to discharge (NCT03364491)
Timeframe: Until hospital discharge, an average of 3 days
Intervention | days (Median) |
---|---|
Tranexamic Acid | 3 |
Placebo | 3 |
(NCT03364491)
Timeframe: within 6 weeks postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 35 |
Placebo | 32 |
This is the number of mothers who were treated with any amount of open-label TXA (not blinded study drug) or another antifibrinolytic (eg., Amicar) (NCT03364491)
Timeframe: within 7 days postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 108 |
Placebo | 109 |
This is the number of mothers who required any of the following types of surgical procedures to control bleeding: laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology (NCT03364491)
Timeframe: within 7 days postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 233 |
Placebo | 231 |
[Key secondary outcome] This is the number of mothers who received treatments and interventions to control bleeding such as: uterotonics such as prostaglandins or methergine, but excluding oxytocin; open label TXA or other antifibrinolytics; transfusion of 1 or more units of fresh frozen plasma, cryoprecipitate, or platelets or administration of any factor concentrates; laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology (NCT03364491)
Timeframe: within 7 days postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 892 |
Placebo | 986 |
Participants were categorized according to the amount of packed red blood cells or whole blood transfused, either as 0 to 3 units, or 4 or more units (NCT03364491)
Timeframe: within 7 days postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 20 |
Placebo | 19 |
This is the number of mothers who received during the first 7 days after delivery a transfusion of 1 or more units of fresh frozen plasma, cryoprecipitate, or platelets, or received any factor concentrates (NCT03364491)
Timeframe: within 7 days postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 29 |
Placebo | 31 |
This is the number of mothers who were treated with uterotonics such as prostaglandins or methergine, but excluding oxytocin, from delivery through 48 hours after delivery. (NCT03364491)
Timeframe: within 48 hours postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 649 |
Placebo | 732 |
[Key secondary outcome] This is the number of mothers who experienced a thromboembolic event, ischemic stroke, or myocardial infarction during the 6 weeks after delivery. (NCT03364491)
Timeframe: within 6 weeks postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 12 |
Placebo | 13 |
[Major secondary outcome] The surgeon or anesthesiologist estimated the blood loss during the delivery in milliliters, which was recorded in the anesthesia record and/or operative report (NCT03364491)
Timeframe: From skin incision to transfer from operating room, average of 1 hour
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 339 |
Placebo | 368 |
Participants were monitored from delivery until hospital discharge or 7 days after delivery (postpartum), whichever is sooner. This is the number of mothers who died for any reason, or had a blood transfusion of 1 or more units (of packed red blood cells, including whole blood or cell saver). (NCT03364491)
Timeframe: by hospital discharge or by 7 days postpartum, whichever is sooner
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 201 |
Placebo | 233 |
[Key Secondary Outcome] This is the number of mothers who experienced any of the following infectious complications in the 6 weeks after delivery: endometritis, surgical site infection, pelvic abscess (NCT03364491)
Timeframe: within 6 weeks postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 162 |
Placebo | 125 |
This is the number of mothers who experienced seizure activity, confirmed by central review, whose onset is after enrollment (NCT03364491)
Timeframe: within 6 weeks postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 2 |
Placebo | 0 |
Plasma TxA concentrations measured from blood samples taken upon arrival in the ICU (NCT03376061)
Timeframe: on arrival in ICU within 3 hours
Intervention | microgram per milliliter per kilogram (Mean) |
---|---|
Topical TxA (Intervention) | 0.58 |
Intravenous TxA (Control) | 1.10 |
Number of hours participants spent in the intensive care unit (ICU) (NCT03376061)
Timeframe: Number of hours spent in ICU from arrival to exit (collected at the Post-Operative Visit).
Intervention | hours (Median) |
---|---|
Topical TxA (Intervention) | 23 |
Intravenous TxA (Control) | 26 |
Cumulative volume (mL) of fluid collected from mediastinal drainage tubes 24 hours after the surgical procedure (NCT03376061)
Timeframe: Fluid collected in the first 24 hours after the surgical procedure
Intervention | mL (Median) |
---|---|
Topical TxA (Intervention) | 500 |
Intravenous TxA (Control) | 540 |
The occurrence of death due to any cause (NCT03376061)
Timeframe: Patients will be followed post-operatively until hospital discharge
Intervention | Participants (Count of Participants) |
---|---|
Topical TxA (Intervention) | 1 |
Intravenous TxA (Control) | 1 |
Patients requiring a red blood cell transfusion (NCT03376061)
Timeframe: Intra-operative and post-operative RBC transfusions
Intervention | Participants (Count of Participants) |
---|---|
Topical TxA (Intervention) | 19 |
Intravenous TxA (Control) | 23 |
Occurrence of re-operation for the purpose of bleeding or cardiac tamponade (NCT03376061)
Timeframe: Patients will be followed post-operatively until hospital discharge
Intervention | Participants (Count of Participants) |
---|---|
Topical TxA (Intervention) | 0 |
Intravenous TxA (Control) | 1 |
Patients experiencing a post-operative seizure (NCT03376061)
Timeframe: Patients will be followed post-operatively until hospital discharge
Intervention | Participants (Count of Participants) |
---|---|
Topical TxA (Intervention) | 0 |
Intravenous TxA (Control) | 1 |
To determine the impact of perioperative administration of Tranexamic Acid on transfusion rates in major burn surgeries. (NCT02753816)
Timeframe: First burn surgery to hospital discharge
Intervention | Patients with 1 or more transfusions (Number) |
---|---|
Tranexamic Acid | 2 |
Placebo | 3 |
To determine the impact of Tranexamic Acid on total hospital length of stay by comparing the hospital admission date and the hospital discharge date. This determination will take into account current burn size and location, procedures performed and their effect on wound healing and skin graft survival. (NCT02753816)
Timeframe: Hospital admission to hospital discharge
Intervention | Days (Median) |
---|---|
Tranexamic Acid | 23 |
Placebo | 9 |
To determine the impact of perioperative administration of Tranexamic Acid on blood loss in major burn surgeries. (NCT02753816)
Timeframe: Intraoperative, average 122 minutes
Intervention | mL (Median) |
---|---|
Tranexamic Acid | 100 |
Placebo | 325 |
1 review available for tranexamic acid and Kidney Failure
Article | Year |
---|---|
Risks of harms using antifibrinolytics in cardiac surgery: systematic review and network meta-analysis of randomised and observational studies.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Proced | 2012 |
2 trials available for tranexamic acid and Kidney Failure
Article | Year |
---|---|
Comparison of epsilon aminocaproic acid and tranexamic Acid in thoracic aortic surgery: clinical efficacy and safety.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aorta, Thoracic; Blood Loss, Surgical; Blood Tran | 2013 |
[Aprotinin in cardiac surgery: more risks than usefulness?].
Topics: Aminocaproates; Antifibrinolytic Agents; Aprotinin; Cardiac Surgical Procedures; Female; Hemostatics | 2006 |
10 other studies available for tranexamic acid and Kidney Failure
Article | Year |
---|---|
Tranexamic acid and convulsive seizures after off-pump coronary artery bypass surgery: the role of renal insufficiency.
Topics: Adult; Aged; Antifibrinolytic Agents; Coronary Artery Bypass, Off-Pump; Female; Glomerular Filtratio | 2019 |
Tranexamic acid and convulsive seizures after isolated coronary artery bypass surgery: the role of cardiopulmonary bypass and renal function.
Topics: Aged; Antifibrinolytic Agents; Cardiopulmonary Bypass; Coronary Artery Bypass; Female; Glomerular Fi | 2020 |
Utility of thromboelastography in managing acquired Factor VIII inhibitor associated massive haemorrhage.
Topics: Antifibrinolytic Agents; Blood Coagulation Factors; Blood Transfusion; Endometrial Neoplasms; Factor | 2013 |
Pharmacokinetic modeling of tranexamic acid for patients undergoing cardiac surgery with normal renal function and model simulations for patients with renal impairment.
Topics: Aged; Antifibrinolytic Agents; Cardiopulmonary Bypass; Computer Simulation; Female; Humans; Kidney; | 2015 |
The risks of aprotinin and tranexamic acid in cardiac surgery: a one-year follow-up of 1188 consecutive patients.
Topics: Adult; Aged; Antifibrinolytic Agents; Aprotinin; Cardiac Surgical Procedures; Coronary Artery Bypass | 2008 |
Renal dysfunction in cardiac surgery: identifying potential risk factors.
Topics: Aged; Antifibrinolytic Agents; Aprotinin; Cardiopulmonary Bypass; Hemostatics; Humans; Middle Aged; | 2009 |
Comparative analysis of antifibrinolytic medications in pediatric heart surgery.
Topics: Aminocaproates; Antifibrinolytic Agents; Aprotinin; Cardiac Surgical Procedures; Chi-Square Distribu | 2012 |
The risk associated with aprotinin in cardiac surgery.
Topics: Adult; Aminocaproates; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Pr | 2006 |
The risk associated with aprotinin in cardiac surgery.
Topics: Adult; Aminocaproates; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Pr | 2006 |
The risk associated with aprotinin in cardiac surgery.
Topics: Adult; Aminocaproates; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Pr | 2006 |
The risk associated with aprotinin in cardiac surgery.
Topics: Adult; Aminocaproates; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Pr | 2006 |
Pro: Aprotinin has a good efficacy and safety profile relative to other alternatives for prevention of bleeding in cardiac surgery.
Topics: Aminocaproic Acid; Animals; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Procedures; Drug Hyper | 2006 |
Effect of aprotinin on renal dysfunction in patients undergoing on-pump and off-pump cardiac surgery: a retrospective observational study.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surg | 2008 |